Avoro Capital Advisors LLC: CYTOKINETICS INC (CYTK): Quarterly 13F Position History
As of Q2 2026, Avoro Capital Advisors LLC reported 4,999,999 shares of CYTOKINETICS INC (CYTK), worth $425.9M and representing 3.8% of its 13F equity book. Quarter-over-quarter share count change: + 1,666,666 (+50.0%) . The position first appeared in Q2 2016 and has been disclosed across 41 13F-HR filings in Pactolio's tracked window.
- 4,999,999Shares Held (Latest Filing)
- $425.9MReported Market Value (Latest Filing)
- 3.8%Portfolio Weight (% of 13F Equity Book)
- +1,666,666Quarter-over-Quarter Share Change
- +$206.2MQuarter-over-Quarter Value Change
- 4,999,999Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 41 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q2 2026 | 4,999,999 | +1,666,666 | +50.0% | $425.9M | 3.8% | $85.2 |
| Q1 2026 | 3,333,333 | +3,333,333 | – | $219.7M | 2.2% | $65.9 |
| Q4 2025 | 0 | 0 | – | $0 | 0.0% | – |
| Q3 2025 | 0 | 0 | – | $0 | 0.0% | – |
| Q2 2025 | 0 | 0 | – | $0 | 0.0% | – |
| Q1 2025 | 0 | 0 | – | $0 | 0.0% | – |
| Q4 2024 | 0 | 0 | – | $0 | 0.0% | – |
| Q3 2024 | 0 | 0 | – | $0 | 0.0% | – |
| Q2 2024 | 0 | 0 | – | $0 | 0.0% | – |
| Q1 2024 | 0 | 0 | – | $0 | 0.0% | – |
| Q4 2023 | 0 | 0 | – | $0 | 0.0% | – |
| Q3 2023 | 0 | 0 | – | $0 | 0.0% | – |
| Q2 2023 | 0 | 0 | – | $0 | 0.0% | – |
| Q1 2023 | 0 | 0 | – | $0 | 0.0% | – |
| Q4 2022 | 0 | 0 | – | $0 | 0.0% | – |
| Q3 2022 | 0 | 0 | – | $0 | 0.0% | – |
| Q2 2022 | 0 | 0 | – | $0 | 0.0% | – |
| Q1 2022 | 0 | 0 | – | $0 | 0.0% | – |
| Q4 2021 | 0 | 0 | – | $0 | 0.0% | – |
| Q3 2021 | 0 | 0 | – | $0 | 0.0% | – |
| Q2 2021 | 0 | 0 | – | $0 | 0.0% | – |
| Q1 2021 | 0 | 0 | – | $0 | 0.0% | – |
| Q4 2020 | 0 | 0 | – | $0 | 0.0% | – |
| Q3 2020 | 0 | 0 | – | $0 | 0.0% | – |
| Q2 2020 | 0 | 0 | – | $0 | 0.0% | – |
| Q1 2020 | 0 | 0 | – | $0 | 0.0% | – |
| Q4 2019 | 0 | 0 | – | $0 | 0.0% | – |
| Q3 2019 | 0 | 0 | – | $0 | 0.0% | – |
| Q2 2019 | 0 | 0 | – | $0 | 0.0% | – |
| Q1 2019 | 0 | 0 | – | $0 | 0.0% | – |
| Q4 2018 | 0 | 0 | – | $0 | 0.0% | – |
| Q3 2018 | 0 | 0 | – | $0 | 0.0% | – |
| Q2 2018 | 0 | 0 | – | $0 | 0.0% | – |
| Q1 2018 | 0 | 0 | – | $0 | 0.0% | – |
| Q4 2017 | 0 | 0 | – | $0 | 0.0% | – |
| Q3 2017 | 0 | 0 | – | $0 | 0.0% | – |
| Q2 2017 | 0 | 0 | – | $0 | 0.0% | – |
| Q1 2017 | 0 | 0 | – | $0 | 0.0% | – |
| Q4 2016 | 0 | 0 | – | $0 | 0.0% | – |
| Q3 2016 | 0 | 503,900 | -100.0% | $0 | 0.0% | – |
| Q2 2016 | 503,900 | – | – | $4.8M | 1.1% | $9.5 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.
When did Avoro Capital Advisors LLC first disclose a CYTK position in 13F-HR filings?
Avoro Capital Advisors LLC first reported CYTOKINETICS INC (CYTK) on its 13F-HR filing for the period ending 2016-06-30 (Q2 2016). The position has appeared on 41 reported quarters within Pactolio's tracked window.
What was Avoro Capital Advisors LLC's most recent quarter-over-quarter share-count change in CYTK?
Between Q1 2026 and Q2 2026, Avoro Capital Advisors LLC added 1,666,666 shares of CYTK (+50.0%), bringing the total reported position to 4,999,999 shares at a market value of $425.9M.
Does the implied price-per-share represent Avoro Capital Advisors LLC's cost basis in CYTK?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.